Julia C Gage

Summary

Affiliation: Health Resources and Services Administration
Country: USA

Publications

  1. ncbi request reprint Follow-up care of women with an abnormal cytology in a low-resource setting
    Julia C Gage
    Health Resources and Services Administration, 5600 Fishers Lane, Room 18 41, Rockville, MD, USA
    Cancer Detect Prev 27:466-71. 2003
  2. pmc Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta
    Philip E Castle
    Global Cancer Imitative, Chestertown, MD, USA
    BMC Infect Dis 13:5. 2013
  3. pmc Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men
    Vikrant V Sahasrabuddhe
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
    J Infect Dis 207:392-401. 2013
  4. pmc Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S78-84. 2013
  5. pmc Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S69-77. 2013
  6. pmc Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S64-8. 2013
  7. pmc Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S56-63. 2013
  8. pmc Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S36-42. 2013
  9. pmc Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S43-9. 2013
  10. pmc Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S50-5. 2013

Detail Information

Publications24

  1. ncbi request reprint Follow-up care of women with an abnormal cytology in a low-resource setting
    Julia C Gage
    Health Resources and Services Administration, 5600 Fishers Lane, Room 18 41, Rockville, MD, USA
    Cancer Detect Prev 27:466-71. 2003
    ..We ascertained the follow-up care after an abnormal cytology (Papanicolaou) screening in the San Marti;n region of PerĂº and assessed the status of women who had not received adequate care...
  2. pmc Human papillomavirus genotypes detected in clinician-collected and self-collected specimens from women living in the Mississippi Delta
    Philip E Castle
    Global Cancer Imitative, Chestertown, MD, USA
    BMC Infect Dis 13:5. 2013
    ..The aim of this analysis was to report the age-specific prevalence of HPV in this population...
  3. pmc Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men
    Vikrant V Sahasrabuddhe
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20852, USA
    J Infect Dis 207:392-401. 2013
    ....
  4. pmc Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S78-84. 2013
    ..It is not clear how many negative posttreatment Pap or cotest results are needed to ensure adequate safety against CIN 2+ before returning to extended retesting intervals...
  5. pmc Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S69-77. 2013
    ..An important question is how many subsequent negative Pap results, or negative Pap and human papillomavirus (HPV) cotest results, are needed before returning to an extended retesting interval...
  6. pmc Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S64-8. 2013
    ..To inform the management of Pap test abnormalities among women aged 21 to 24 years, who have extremely low cancer risks, we compared risks of CIN 3+ among women aged 21 to 24 versus 25 to 29 years or 30 to 64 years...
  7. pmc Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S56-63. 2013
    ..However, the performance of these guidelines in routine clinical practice has not been evaluated...
  8. pmc Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S36-42. 2013
    ..However, despite ample data, the routine clinical performance of HPV testing of women with ASC-US has not been adequately documented...
  9. pmc Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S43-9. 2013
    ..Some authors have suggested that HPV triage might be effective at older ages, when the percentage of HPV positivity among women with LSIL declines...
  10. pmc Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S50-5. 2013
    ..We examined whether HPV testing provides useful risk stratification in this context...
  11. pmc The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Int J Cancer 130:2111-7. 2012
    ....
  12. pmc A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection
    Megan A Clarke
    Division of Cancer Epidemiology and Genetics, DHHS, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    BMC Infect Dis 12:33. 2012
    ..We examined vaginal pH and the risk of HPV infection, cytological abnormalities, and C. trachomatis infection...
  13. pmc Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Int J Cancer 131:2903-9. 2012
    ..In a challenging low-resource setting with minimal intervention, the careHPV test performed adequately with high specificity but possibly lower sensitivity than HPV DNA tests currently used in controlled situations...
  14. pmc Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20892 7234, USA
    J Low Genit Tract Dis 17:137-41. 2013
    ..For women with these pathologic findings, we assessed their short-term risk of high-grade histopathologic diagnosis in the Calgary Health Region where ECC was routinely performed...
  15. pmc Comparative performance of human papillomavirus DNA testing using novel sample collection methods
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, MSC 7231, Rockville, MD 20852, USA
    J Clin Microbiol 49:4185-9. 2011
    ..HC2 is likely more clinically specific, although possibly less sensitive, than either PCR test. Thus, use of HC2 on cervicovaginal specimens for screening could result in fewer referrals compared to LA and Amplicor...
  16. ncbi request reprint Assuring adequate health insurance: results of the National Survey of Children with Special Health Care Needs
    Lynda Honberg
    Maternal and Child Health Bureau, Health Resources and Services Administration, Rockville, Maryland 20857, USA
    Pediatrics 115:1233-9. 2005
    ....
  17. ncbi request reprint Cervical histopathology variability among laboratories: a population-based statewide investigation
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services DHHS, Bethesda, MD, USA
    Am J Clin Pathol 139:330-5. 2013
    ..In conclusion, the frequency of diagnoses requiring special staining (p16(INK4a) immunostaining) to adjudicate equivocal CIN2 will be sizable and vary between laboratories, especially if extended to a fraction of CIN1 lesions...
  18. pmc Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines
    Hormuzd A Katki
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, Bethesda, MD 20892, USA
    J Low Genit Tract Dis 17:S28-35. 2013
    ..To promote management that is consistent with accepted practice, new guidelines incorporating cotesting should aim to achieve equal management of women at equal risk of cervical intraepithelial neoplasia grade 3 and cancer (CIN 3+)...
  19. ncbi request reprint Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM
    Nicolas Wentzensen
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA
    AIDS 26:2185-92. 2012
    ..Both approaches have limited reproducibility and sensitivity for detecting anal cancer precursors. We evaluated biomarkers for human papillomavirus (HPV)-related disease in a population of HIV-infected MSM...
  20. pmc A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria
    Megan A Clarke
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA
    Infect Agent Cancer 6:12. 2011
    ..abstract:..
  21. pmc Human papillomavirus testing in the prevention of cervical cancer
    Mark Schiffman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 103:368-83. 2011
    ..The greatest potential for reduction in cervical cancer rates from HPV screening is in low-resource regions that can implement infrequent rounds of low-cost HPV testing and treatment...
  22. pmc Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20892, USA
    Am J Obstet Gynecol 203:481.e1-9. 2010
    ..ECC is routinely performed in the Calgary Health Region colposcopy clinics, permitting a look at its real-world utility...
  23. pmc Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions
    Julia C Gage
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 7013, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 19:1668-74. 2010
    ..Compared with pooled-probe testing, measuring HPV genotype-specific persistence might better predict subsequent grade 3 cervical intraepithelial neoplasia (CIN3)...
  24. ncbi request reprint Number of cervical biopsies and sensitivity of colposcopy
    Julia C Gage
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Obstet Gynecol 108:264-72. 2006
    ..To examine the influence that type of medical training and number of biopsies have on sensitivity of colposcopically guided biopsies...